Reuters Market Eye - Shares in drugmaker Lupin down 6.7 percent after April-June domestic revenue falls 5 percent from a year ago, along with a 12 percent drop in sales in Japan.
The government's new drug pricing regulation, which seeks to cap prices of medicines deemed essential, has also had an impact on India sales, Lupin's Group President Nilesh Gupta told Reuters.
Meanwhile, a drug manufacturing contract that was deferred hurt sales at Lupin's Japanese unit, Gupta added.
Lupin had earlier reported consolidated net profit rose 43 percent to 4.01 billion rupees, while consolidated net sales rose 9.1 percent.
(Reporting by Kaustubh Kulkarni)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app